Abstract
Introduction: Coronavirus 2 disease is associated with increased mortality and morbidity in chronic hemodialysis patients METHODS: A retrospective, observational case-control pilot study was conducted on consecutive hemodialysis outpatients (cases) and control group of individuals with preserved renal function. Complete SARS-CoV-2 vaccination with BNT162b2 mRNA vaccine, followed by determination of serum antibodies after the second dose, were required from participants in both groups. Previous COVID-19 was an exclusion criterium.
Results: 21 hemodialysis patients (M:F = 13:8, mean age 67.5 ± 13.4) and 16 controls without chronic kidney disease (M:F = 4:12, mean age 46.8 ± 12.7) were included. Hemodialysis patients had lower mean titers of serum antibodies to the SARS-CoV-2 spike antigen compared with controls (492.39 vs 1901.20 IU/mL, respectively; p < 0.001), a finding that was confirmed in the age-matched analysis on 18 participants (580.8 vs 1836.4 IU/mL, p = 0.006).
Conclusions: This study supports the finding of hyporesponsiveness to mRNA vaccination among hemodialysis patients.
Keywords: Antibody activity; COVID-19; Hemodialysis; mRNA vaccines.
【저자키워드】 COVID-19, Hemodialysis, mRNA vaccines., Antibody activity, 【초록키워드】 mRNA vaccination, Chronic kidney disease, coronavirus 2, renal function, mRNA vaccines, Antigen, morbidity, Patient, Control, Case-control, age, serum antibody, disease, patients, SARS-CoV-2 vaccination, BNT162b2 mRNA vaccine, Outpatient, retrospective, Analysis, Support, control group, pilot study, second dose, individual, participant, increased mortality, exclusion, hyporesponsiveness, required, conducted, chronic hemodialysis patient, in both groups, preserved, the SARS-CoV-2, 【제목키워드】 response,